Skip to main content
Premium Trial:

Request an Annual Quote

InVivoScribe Gets European OK for Leukemia Mutation Assay

NEW YORK (GenomeWeb News) – InVivoScribe Technologies has received the CE IVD Mark for its LeukoStrat FLT3 Mutation Assay, the San Diego-based firm said today.

The PCR-based assay detects internal tandem duplications and point mutations in the FLT3 gene from whole blood or bone marrow in patients with acute myelogenous leukemia. According to privately held InVivoScribe, the mutation status of the FLT3 receptor gene is the most important prognostic indicator of disease outcome in cytogenically normal AML.

The firm said that the World Health Organization has recommended evaluation of FLT3 mutation status in CN-AML to assist in the clinical management of patients with AML.

"The FLT3 assay is the first of what we expect will be a number of CE marked LeukoStrat assays we will introduce to test key prognostic markers in hematologic malignancies," InVivoScribe CSO and CEO Jeffrey Miller said in a statement.

Filed under

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.